In IMpower 133 trial, both PD-L1 expression and TMB status poorly correlated with clinical outcomes of SCLC patients treated with atezolizumab plus chemotherapy, making the field of predictive biomarkers for combined therapies even more challenging (63). The gene discussed is CD274; the disease is small cell lung carcinoma.